#USA #New York City #Lakewood-Amedex #Bisphosphocin #Kelvin Cooper

Lakewood-Amedex Biotherapeutics to Highlight Innovations at Key Conferences in October

Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT), a clinical-stage biotechnology firm, is set to make waves this October with CEO Kelvin Cooper, Ph.D., participating in three pivotal industry conferences. These events aim to elevate the company's position in the competitive biotech landscape, particularly in the realm of antimicrobial therapies.

A Focus on Antimicrobial Innovation

Lakewood-Amedex is at the forefront of developing a new class of fast-acting antimicrobials known as the Bisphosphocin® class. These innovative treatments are designed to combat infectious diseases, especially those caused by antibiotic-resistant bacteria, including strains such as MRSA and VRE, which pose significant public health challenges. The company's research endeavors are directed towards enhancing patient outcomes through effective treatment solutions.

Upcoming Events

Maxim Growth Summit

• - Date: October 13-14, 2026
• - Location: Hard Rock Hotel, New York City

Dr. Kelvin Cooper will kick off the month by attending the Maxim Growth Summit, where he will engage with investors and industry leaders. This summit serves as a platform for sharing insights on market trends and investment opportunities in the biotech sector.

ThinkEquity Conference

• - Date: October 15, 2026
• - Location: The Mandarin Oriental Hotel, New York City

On October 15, Dr. Cooper will present at the ThinkEquity Conference, focusing on the novel antimicrobial compound Nu-3. His presentation entitled, "Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In-Vitro Activity Against Resistant Pathogens for the Treatment of Infected Diabetic Foot Ulcers" is scheduled for 3:30 PM. This session is particularly important as it highlights the company's commitment to advancing solutions for complex medical conditions.

IDWeek

• - Date: October 21-24, 2026
• - Location: Walter E. Washington Convention Center, Washington D.C. (Hybrid Format Available)

Closing the month, Lakewood-Amedex will participate in IDWeek, a prominent event dedicated to infectious diseases. Dr. Cooper will present compelling preclinical data regarding Nu-3, providing attendees with insights into its efficacy and potential impact.

Strategic Engagement

The participation in these conferences represents an invaluable opportunity for Lakewood-Amedex to engage directly with key stakeholders, including investors, fellow researchers, and healthcare professionals. By showcasing their research and development progress, particularly concerning the Bisphosphocin® antimicrobial technology, the company aims to build brand recognition and attract further investment.

About Lakewood-Amedex Biotherapeutics, Inc.

Founded with a mission to revolutionize treatments for infectious diseases, Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) stands out for its dedication to developing fast-acting, broad-spectrum antimicrobial solutions. Through their innovative research, they seek to mitigate the threats posed by resistant bacterial strains. For more updated information and to track their progress, visit their official website lakewoodamedex.com.

As the health landscape continues to evolve, Lakewood-Amedex's initiatives are more crucial than ever, paving the way for innovative solutions in the ongoing fight against infectious diseases. The upcoming conferences will certainly be a significant milestone in demonstrating their ongoing commitment to healthcare advancements.